MDR Vivacit-E Elevated Study
← catalyst calendarNCT07150221 · readout ≤ 499 d
Sponsored by Zimmer Biomet (industry) · ZBH — their whole pipeline →.
Phase
—
Status
Enrolling by invitation
Study type
Observational
Enrollment
52estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-07 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Osteoarthritis (OA) of the Hip
- Avascular Necrosis of Bone of Hip
- Protrusio Acetabuli
- Traumatic Arthropathy-Hip
- Slipped Capital Femoral Epiphyses
- Fused Hip
- Fracture of Pelvis
- Diastrophic Variant
Intervention
- Device: Vivacit-E Elevated Liners
Primary outcome
what the primary-completion date above is the date OFSurvival of the Implant System via Adverse Events
measured 10 years
Permalink · ZBH's whole pipeline · Catalyst calendar · Every registered study · What changed